H.R. 7640 — To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as "orphan drugs").

Summary

This bill reauthorizes through FY2027 the Food and Drug Administration's Orphan Products Grants Program, which supports clinical research and product development for rare diseases and conditions.

Full Text

Related Legislation

S. 4348FDASLA Act of 2022
2022-07-13Placed on Senate Legislative Calendar under General Orders. Calendar No. 444.
Related

Legislative Actions

2022-05-03
Introduced in House
2022-05-03
Introduced in House
2022-05-03
Referred to the House Committee on Energy and Commerce.

To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as "orphan drugs").

Sponsors

Subjects

Summary

Full Text

Related Legislation

Legislative Actions

Ask about this bill